Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Serum DCAMKL1 Pre and Post Treatment in Patients With Pancreatic Cancer

This study is enrolling participants by invitation only.
Sponsor:
Information provided by (Responsible Party):
University of Oklahoma
ClinicalTrials.gov Identifier:
NCT01580241
First received: April 17, 2012
Last updated: NA
Last verified: April 2012
History: No changes posted

April 17, 2012
April 17, 2012
August 2011
June 2013   (final data collection date for primary outcome measure)
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Serum DCAMKL1 Pre and Post Treatment in Patients With Pancreatic Cancer
Expression Patterns of Stem Cell Marker Doublecortin and CaM Kinase-Like-1 (DCAMKL-1) in Human Pancreatic Adenocarcinoma

The investigators believe DCAMKL-1 is a stem cell tumor marker and is elevated in patients with pancreatic cancer. The investigators would like to analyze its expression pre and post treatment, to gauge the correlation between current pancreatic cancer therapies and the expression of DCAMKL-1

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Human patients with pancreatic cancer undergo various treatments for pancreatic cancer. We will examine the expression of Dcamkl-1 pre and post therapy (including, chemotherapy only, surgery only, neoadjuvant and adjuvant therapies) to correlate treatment with a change in DCAMKl-1 expression.

Pancreatic Cancer
Not Provided
  • Surgery group
    Patients with pancreatic cancer who undergo surgical treatment only
  • Chemotherapy group
    Patients with pancreatic cancer who undergo chemotherapy treatment only
  • Neoadjuvant group
    Patients with pancreatic cancer who undergo neoadjuvant chemotherapy and surgery
  • Adjuvant group
    Patients with pancreatic cancer who undergo surgery followed by chemotherapy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Enrolling by invitation
100
June 2013
June 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • pancreatic cancer

Exclusion Criteria:

  • age < 18, history of other types of cancer
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01580241
DCAMKL1 Panc CA pre/post surg
No
University of Oklahoma
University of Oklahoma
Not Provided
Principal Investigator: Courtney Houchen, MD University of Oklahoma
University of Oklahoma
April 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP